Drug intelligence / Profile preview

SM-001

Development stage
Phase 1
Lead developer
Advanced Integrative Medical Science Institute
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration
Oral
01

Overview

**SM-001** is an investigational standardized ayahuasca analog developed by Advanced Integrative Medical Science Institute. It is an oral hot-water decoction prepared from proprietary clonal cultivars of *Banisteriopsis caapi* and *Psychotria viridis*. The registered Phase 1 program evaluates single-dose safety, dose range, and systemic exposure to dimethyltryptamine, harmine, tetrahydroharmine, and harmaline in healthy adults; the program is associated with development for major depressive disorder and post-traumatic stress disorder. Its pharmacology is expected to reflect the combined activity of dimethyltryptamine at serotonergic receptors and beta-carboline monoamine oxidase A inhibition, which enables oral dimethyltryptamine exposure. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05894902))

Other names
Ayahuasca analog
02

Targets

HTR2A (Serotonin receptor 5-HT2A)MAOA (Monoamine oxidase A)SIGMAR1 (Sigma non-opioid intracellular receptor 1)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on SM-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM-001.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call